Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Anthony Elias

Concepts (665)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
110
2026
2380
5.840
 Why?
Antineoplastic Combined Chemotherapy Protocols
96
2025
1958
3.750
 Why?
Sarcoma
33
2025
204
3.640
 Why?
Receptors, Estrogen
22
2021
401
2.210
 Why?
Triple Negative Breast Neoplasms
14
2024
218
2.140
 Why?
Hematopoietic Stem Cell Transplantation
36
2011
698
1.840
 Why?
Carcinoma, Small Cell
19
2003
172
1.640
 Why?
Soft Tissue Neoplasms
14
2022
128
1.500
 Why?
Carcinoma, Ductal, Breast
7
2018
89
1.410
 Why?
Neoadjuvant Therapy
18
2025
465
1.270
 Why?
Antineoplastic Agents
31
2023
2207
1.170
 Why?
Neoplasm Staging
37
2026
1467
1.090
 Why?
Neoplasm Recurrence, Local
20
2022
1146
1.080
 Why?
Receptors, Progesterone
13
2020
243
1.040
 Why?
Combined Modality Therapy
52
2024
1264
0.960
 Why?
Lung Neoplasms
38
2003
2662
0.960
 Why?
Doxorubicin
24
2025
396
0.930
 Why?
Biomarkers, Tumor
17
2022
1320
0.920
 Why?
Paclitaxel
14
2024
256
0.870
 Why?
Bone Marrow Transplantation
27
1998
297
0.860
 Why?
CTLA-4 Antigen
1
2025
105
0.860
 Why?
Mastectomy
9
2018
181
0.830
 Why?
Bone Neoplasms
7
2025
255
0.810
 Why?
Antibodies, Monoclonal, Humanized
10
2025
992
0.760
 Why?
Antineoplastic Agents, Alkylating
5
2018
72
0.710
 Why?
Female
170
2026
78636
0.700
 Why?
Receptors, Androgen
7
2018
148
0.690
 Why?
Disease-Free Survival
24
2023
766
0.670
 Why?
Humans
228
2026
145140
0.670
 Why?
Middle Aged
112
2025
36126
0.630
 Why?
Maytansine
3
2021
18
0.620
 Why?
Antineoplastic Agents, Hormonal
10
2018
192
0.620
 Why?
Liposarcoma
4
2023
31
0.620
 Why?
Neoplasm Metastasis
23
2024
688
0.570
 Why?
Adult
114
2025
40665
0.560
 Why?
Chemotherapy, Adjuvant
23
2023
423
0.550
 Why?
Dioxoles
2
2015
9
0.540
 Why?
Tetrahydroisoquinolines
2
2015
8
0.540
 Why?
Cyclophosphamide
31
2024
266
0.530
 Why?
Androgen Receptor Antagonists
6
2021
35
0.490
 Why?
Ifosfamide
19
1998
39
0.490
 Why?
Phenylthiohydantoin
5
2017
44
0.490
 Why?
Aged
65
2025
26096
0.480
 Why?
Dasatinib
1
2016
58
0.480
 Why?
Trastuzumab
10
2024
118
0.460
 Why?
Neoplasms, Hormone-Dependent
3
2012
33
0.460
 Why?
Treatment Outcome
43
2024
11741
0.440
 Why?
Drug Administration Schedule
24
2018
781
0.430
 Why?
Carboplatin
21
2016
161
0.420
 Why?
Estrogen Receptor alpha
5
2021
151
0.420
 Why?
Granulocyte Colony-Stimulating Factor
11
2002
90
0.420
 Why?
Carcinoma, Non-Small-Cell Lung
17
2001
1188
0.400
 Why?
Clinical Trials as Topic
19
2018
1058
0.390
 Why?
Estrogens
6
2018
367
0.390
 Why?
Medical Oncology
6
2026
338
0.370
 Why?
Dacarbazine
9
2018
100
0.370
 Why?
Tamoxifen
9
2018
191
0.350
 Why?
Survival Rate
19
2021
2087
0.350
 Why?
Survival Analysis
23
2010
1371
0.340
 Why?
Neoplasms
20
2009
2900
0.330
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2013
977
0.330
 Why?
Prognosis
22
2021
4310
0.330
 Why?
Venous Thromboembolism
3
2020
328
0.330
 Why?
Programmed Cell Death 1 Receptor
2
2025
264
0.330
 Why?
Pyrimidines
3
2020
530
0.320
 Why?
Neoplasms, Second Primary
3
2022
102
0.320
 Why?
Dose-Response Relationship, Drug
17
2017
2026
0.320
 Why?
Carcinoma, Intraductal, Noninfiltrating
3
2022
61
0.320
 Why?
Antibodies, Monoclonal
9
2024
1505
0.310
 Why?
Taxoids
7
2023
114
0.310
 Why?
Remission Induction
16
2002
306
0.310
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
8
1999
161
0.300
 Why?
Breast Neoplasms, Male
3
2018
29
0.300
 Why?
Drug Resistance, Neoplasm
7
2017
881
0.280
 Why?
Gene Expression Regulation, Neoplastic
11
2018
1442
0.280
 Why?
Neoplastic Cells, Circulating
2
2020
81
0.280
 Why?
Mesna
12
1998
15
0.270
 Why?
Sarcoma, Ewing
3
2022
103
0.260
 Why?
Leiomyosarcoma
2
2018
29
0.250
 Why?
Cisplatin
14
2000
344
0.250
 Why?
Sternum
1
2006
27
0.240
 Why?
Immunohistochemistry
5
2016
1713
0.240
 Why?
Immunoconjugates
3
2024
138
0.240
 Why?
Tumor Microenvironment
4
2024
733
0.230
 Why?
Mastectomy, Segmental
2
2009
107
0.230
 Why?
Chondrosarcoma
1
2025
17
0.220
 Why?
Carcinoma, Ductal
1
2005
10
0.220
 Why?
Peripheral Blood Stem Cell Transplantation
2
2002
35
0.220
 Why?
Melphalan
10
2002
43
0.220
 Why?
Isocitrate Dehydrogenase
1
2025
72
0.220
 Why?
Pyridines
2
2025
608
0.220
 Why?
Transplantation, Autologous
19
2002
298
0.220
 Why?
Cell Adhesion Molecules
2
2021
181
0.220
 Why?
Carcinoma
2
2008
224
0.210
 Why?
Lymph Nodes
1
2007
502
0.210
 Why?
Male
66
2025
72664
0.210
 Why?
Protein Kinase Inhibitors
4
2019
979
0.210
 Why?
Risk Reduction Behavior
2
2016
217
0.210
 Why?
Drug Evaluation
19
1998
79
0.210
 Why?
Glycine
1
2025
186
0.200
 Why?
Adjuvants, Immunologic
3
2022
243
0.200
 Why?
Ribonuclease III
2
2016
43
0.200
 Why?
Deoxycytidine
4
2020
220
0.200
 Why?
Survivors
3
2016
522
0.200
 Why?
Ovarian Neoplasms
3
2022
594
0.200
 Why?
Thiotepa
13
2002
21
0.200
 Why?
Alkylating Agents
3
2000
24
0.190
 Why?
Hodgkin Disease
4
2016
171
0.190
 Why?
DEAD-box RNA Helicases
2
2016
83
0.190
 Why?
Triazoles
2
2022
187
0.190
 Why?
Weight Loss
4
2016
845
0.190
 Why?
Gene Expression Profiling
6
2017
1763
0.190
 Why?
Behavior Therapy
2
2016
294
0.190
 Why?
Disease Management
5
2020
651
0.180
 Why?
Aged, 80 and over
14
2021
8318
0.180
 Why?
Employment
1
2024
184
0.180
 Why?
Mutation
4
2025
4071
0.180
 Why?
Obesity
4
2018
3097
0.180
 Why?
Hydrazines
1
2022
37
0.180
 Why?
Overweight
3
2016
609
0.180
 Why?
Salvage Therapy
6
2010
165
0.180
 Why?
Carcinoma in Situ
2
2012
44
0.180
 Why?
Circulating Tumor DNA
1
2022
46
0.180
 Why?
Etoposide
10
2001
167
0.170
 Why?
Tumor Cells, Cultured
9
2020
886
0.170
 Why?
Hematologic Diseases
6
2008
66
0.170
 Why?
Sarcoma, Synovial
1
2021
20
0.170
 Why?
Liposarcoma, Myxoid
1
2021
10
0.170
 Why?
Referral and Consultation
1
2007
862
0.170
 Why?
Recombinant Fusion Proteins
1
2024
666
0.170
 Why?
Emergency Medicine
1
2024
282
0.170
 Why?
Endpoint Determination
1
2021
85
0.160
 Why?
Aromatase Inhibitors
4
2021
78
0.160
 Why?
Sentinel Lymph Node Biopsy
3
2017
117
0.160
 Why?
Cell Separation
3
2017
304
0.160
 Why?
Leukocytes, Mononuclear
3
2020
573
0.160
 Why?
Indazoles
1
2020
83
0.160
 Why?
Hematopoietic Stem Cells
5
1996
418
0.160
 Why?
Cancer Care Facilities
1
2020
48
0.160
 Why?
Antigens, Neoplasm
4
2021
271
0.160
 Why?
Time Factors
12
2020
7107
0.160
 Why?
Diphosphonates
1
2020
68
0.150
 Why?
Pyrroles
2
2013
220
0.150
 Why?
Diet
3
2018
1277
0.150
 Why?
Bone Marrow
8
2000
306
0.150
 Why?
Nuclear Medicine
1
2019
9
0.150
 Why?
Hematology
1
2019
21
0.140
 Why?
Bridged-Ring Compounds
4
2023
31
0.140
 Why?
Cell Line, Tumor
9
2017
3539
0.140
 Why?
MCF-7 Cells
5
2017
132
0.140
 Why?
Proportional Hazards Models
6
2020
1325
0.140
 Why?
CA-125 Antigen
2
2013
13
0.140
 Why?
Fluorouracil
7
2013
230
0.140
 Why?
Epithelial-Mesenchymal Transition
1
2020
219
0.140
 Why?
Pyrazoles
2
2022
517
0.140
 Why?
Pulmonary Medicine
1
2019
78
0.140
 Why?
Thromboembolism
1
2019
129
0.140
 Why?
Bayes Theorem
4
2024
419
0.140
 Why?
Benzamides
5
2017
224
0.140
 Why?
Research Design
3
2021
1132
0.140
 Why?
Receptor, Fibroblast Growth Factor, Type 1
1
2018
58
0.130
 Why?
Nitriles
5
2017
207
0.130
 Why?
Tissue Inhibitor of Metalloproteinase-3
1
2017
9
0.130
 Why?
Cyclin-Dependent Kinase 4
1
2018
53
0.130
 Why?
Cell Cycle
1
2021
596
0.130
 Why?
Cyclin-Dependent Kinase 6
1
2018
49
0.130
 Why?
Infusions, Intravenous
10
2020
428
0.130
 Why?
Kaplan-Meier Estimate
6
2018
968
0.130
 Why?
Schwann Cells
1
2017
33
0.130
 Why?
Tetrahydronaphthalenes
1
2017
31
0.130
 Why?
Vaccines
1
2022
388
0.130
 Why?
Sciatic Nerve
1
2017
62
0.130
 Why?
Microbubbles
1
2017
53
0.130
 Why?
Valine
1
2017
82
0.130
 Why?
Betacoronavirus
1
2020
287
0.130
 Why?
Venous Thrombosis
1
2019
195
0.130
 Why?
Societies, Medical
2
2019
898
0.130
 Why?
Amyloid Precursor Protein Secretases
1
2017
78
0.130
 Why?
Lymph Node Excision
3
2015
173
0.130
 Why?
Camptothecin
3
2024
138
0.120
 Why?
Indoles
2
2013
507
0.120
 Why?
Axilla
3
2017
51
0.120
 Why?
Androgen Antagonists
2
2015
91
0.120
 Why?
Sulfonamides
1
2020
583
0.120
 Why?
Cancer-Associated Fibroblasts
1
2016
23
0.120
 Why?
Gonadal Steroid Hormones
1
2018
143
0.120
 Why?
Immunotherapy
2
2018
665
0.120
 Why?
Hematopoietic Cell Growth Factors
2
1995
5
0.120
 Why?
Neoplasms, Germ Cell and Embryonal
2
1995
76
0.120
 Why?
Ultrasonography, Mammary
1
2016
17
0.120
 Why?
Neoplasms, Radiation-Induced
1
2016
100
0.120
 Why?
Antibody Specificity
1
2016
177
0.120
 Why?
Lymphatic Metastasis
3
2017
331
0.120
 Why?
Internship and Residency
2
2024
1264
0.120
 Why?
Anesthesiology
1
2019
178
0.120
 Why?
Tumor Suppressor Protein p53
2
2023
532
0.120
 Why?
Thiazoles
1
2016
140
0.120
 Why?
Follow-Up Studies
6
2025
5411
0.120
 Why?
Neoplasm Invasiveness
3
2016
506
0.120
 Why?
Myelin Sheath
1
2017
166
0.110
 Why?
Maximum Tolerated Dose
1
2016
210
0.110
 Why?
Neoplastic Stem Cells
2
2017
409
0.110
 Why?
Antibiotics, Antineoplastic
1
2016
139
0.110
 Why?
Ambulatory Care
1
2020
608
0.110
 Why?
Benzimidazoles
1
2016
189
0.110
 Why?
Quinolines
1
2016
190
0.110
 Why?
Pneumonia, Viral
1
2020
388
0.110
 Why?
Coronavirus Infections
1
2020
382
0.110
 Why?
Drug Therapy, Combination
4
2014
1043
0.110
 Why?
Recurrence
5
2020
1134
0.110
 Why?
Mammography
1
2016
166
0.110
 Why?
Animals
17
2021
37952
0.110
 Why?
Disease Progression
7
2018
2857
0.100
 Why?
Radiotherapy, Adjuvant
5
2016
221
0.100
 Why?
Homeodomain Proteins
2
2018
522
0.100
 Why?
Brain Edema
1
2014
62
0.100
 Why?
Hepatic Veno-Occlusive Disease
3
2002
12
0.100
 Why?
Administration, Oral
4
2020
862
0.100
 Why?
Antibodies
1
2016
397
0.100
 Why?
Radiotherapy Dosage
3
1999
288
0.100
 Why?
TOR Serine-Threonine Kinases
1
2017
454
0.100
 Why?
Young Adult
10
2025
14176
0.100
 Why?
Vascular Neoplasms
1
2013
18
0.100
 Why?
Clinical Trials, Phase I as Topic
3
2024
50
0.100
 Why?
Testicular Neoplasms
1
1995
111
0.100
 Why?
Comorbidity
5
2017
1657
0.100
 Why?
Radiotherapy
3
2015
204
0.100
 Why?
Apoptosis
6
2023
2434
0.100
 Why?
Epigenesis, Genetic
2
2018
672
0.100
 Why?
Exercise
2
2015
2191
0.100
 Why?
Cellular Reprogramming
1
2014
98
0.100
 Why?
Keratins
2
2017
171
0.100
 Why?
Mercaptoethanol
2
1990
8
0.100
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
3
2022
132
0.100
 Why?
Adenocarcinoma
6
2015
920
0.100
 Why?
Mice
12
2021
18303
0.100
 Why?
Cell Proliferation
6
2017
2504
0.090
 Why?
Gallium Radioisotopes
1
1992
16
0.090
 Why?
Patient Selection
4
2016
733
0.090
 Why?
Bone Marrow Cells
4
2000
320
0.090
 Why?
Protein-Tyrosine Kinases
2
2022
431
0.090
 Why?
Carmustine
10
2001
52
0.090
 Why?
Chromatin
1
2016
553
0.090
 Why?
Anthracyclines
3
2023
49
0.090
 Why?
Adolescent
23
2025
22479
0.090
 Why?
Methotrexate
4
2002
233
0.090
 Why?
Lymphoma, Non-Hodgkin
3
2001
124
0.090
 Why?
Brain Neoplasms
5
2014
1328
0.080
 Why?
Neoplasm, Residual
2
2022
143
0.080
 Why?
Weight Reduction Programs
1
2012
138
0.080
 Why?
Retrospective Studies
12
2023
17247
0.080
 Why?
RNA, Catalytic
1
2012
191
0.080
 Why?
Polydeoxyribonucleotides
2
2002
14
0.080
 Why?
Age Factors
5
2019
3338
0.080
 Why?
Risk Assessment
3
2020
3740
0.080
 Why?
Neutropenia
5
2013
154
0.080
 Why?
Neoplasm Grading
3
2017
310
0.080
 Why?
Multivariate Analysis
4
2013
1546
0.080
 Why?
Leukapheresis
4
2001
27
0.080
 Why?
Carcinoma, Lobular
1
2011
56
0.080
 Why?
Aorta
1
2013
439
0.080
 Why?
Radiosurgery
1
2014
399
0.080
 Why?
Keratin-5
1
2010
44
0.080
 Why?
Biopsy
3
2018
1079
0.080
 Why?
Angiogenesis Inhibitors
1
2012
238
0.080
 Why?
Liver Neoplasms
3
2015
775
0.080
 Why?
Peptide Mapping
1
2010
62
0.080
 Why?
Electrophoresis, Gel, Two-Dimensional
1
2010
110
0.080
 Why?
Molecular Targeted Therapy
3
2018
438
0.080
 Why?
Practice Patterns, Physicians'
1
2019
1365
0.080
 Why?
Piperazines
2
2023
375
0.080
 Why?
Databases, Protein
1
2010
88
0.080
 Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2010
142
0.080
 Why?
Urinary Tract
1
1990
47
0.070
 Why?
Benzenesulfonates
1
2009
23
0.070
 Why?
CD146 Antigen
2
2021
38
0.070
 Why?
Postmenopause
2
2017
391
0.070
 Why?
BRCA2 Protein
1
2009
68
0.070
 Why?
Health Facilities
1
2009
85
0.070
 Why?
Pregnancy Complications, Neoplastic
1
2009
63
0.070
 Why?
Observer Variation
1
2010
356
0.070
 Why?
Thrombophilia
1
2009
89
0.070
 Why?
Patient Care
1
2009
119
0.070
 Why?
Risk Factors
8
2020
10857
0.070
 Why?
Mice, Nude
3
2017
679
0.070
 Why?
Perimenopause
1
2008
69
0.070
 Why?
United States
9
2023
16065
0.070
 Why?
Fibrinolytic Agents
2
2002
297
0.070
 Why?
Bone Marrow Diseases
4
2000
20
0.070
 Why?
In Situ Hybridization
2
2010
318
0.070
 Why?
In Situ Hybridization, Fluorescence
1
2008
323
0.070
 Why?
Blotting, Western
1
2010
1177
0.060
 Why?
Fatigue
3
2018
363
0.060
 Why?
Xenograft Model Antitumor Assays
3
2017
932
0.060
 Why?
Randomized Controlled Trials as Topic
6
2000
1742
0.060
 Why?
Sputum
1
1988
302
0.060
 Why?
Pneumonectomy
3
1997
167
0.060
 Why?
Reproducibility of Results
2
2016
3410
0.060
 Why?
Proto-Oncogene Proteins c-akt
2
2019
440
0.060
 Why?
Quality of Life
2
2015
3194
0.060
 Why?
Neoplasm Proteins
2
2007
441
0.060
 Why?
Clinical Decision-Making
2
2020
362
0.050
 Why?
Life Tables
2
2002
21
0.050
 Why?
Anilides
2
2016
84
0.050
 Why?
New Jersey
1
2024
16
0.050
 Why?
Colony-Stimulating Factors
3
1988
37
0.050
 Why?
Positron-Emission Tomography
1
2006
343
0.050
 Why?
Enzyme Inhibitors
1
2008
820
0.050
 Why?
Predictive Value of Tests
2
2016
2115
0.050
 Why?
MicroRNAs
1
2010
686
0.050
 Why?
Receptor, TIE-2
1
2024
11
0.050
 Why?
Oligonucleotide Array Sequence Analysis
3
2012
749
0.050
 Why?
Granulocytes
4
1995
81
0.050
 Why?
New York
1
2024
128
0.050
 Why?
Growth Substances
3
1988
138
0.050
 Why?
Ricin
2
1997
8
0.050
 Why?
Genes, Neoplasm
1
2004
25
0.050
 Why?
Forecasting
3
2000
388
0.050
 Why?
Thrombocytopenia
3
2013
204
0.050
 Why?
Up-Regulation
2
2017
846
0.050
 Why?
Patient Care Planning
1
2005
170
0.050
 Why?
Activating Transcription Factor 4
1
2023
22
0.050
 Why?
Anticoagulants
2
2019
748
0.050
 Why?
Proteasome Inhibitors
1
2023
41
0.050
 Why?
Signal Transduction
5
2018
5208
0.050
 Why?
Magnetic Resonance Imaging
1
2016
3892
0.050
 Why?
Proto-Oncogene Proteins c-mdm2
1
2023
67
0.050
 Why?
Mammaplasty
2
2016
141
0.050
 Why?
G(M2) Ganglioside
1
2022
1
0.050
 Why?
Injection Site Reaction
1
2022
4
0.050
 Why?
Cyclin E
1
2022
23
0.050
 Why?
Proteomics
1
2010
1185
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2000
116
0.050
 Why?
Treatment Failure
2
2001
360
0.050
 Why?
Luminescent Measurements
1
2003
75
0.050
 Why?
France
2
2019
40
0.050
 Why?
Transcriptome
2
2023
1029
0.050
 Why?
Ribose
1
2022
22
0.050
 Why?
Oncogene Proteins
1
2022
61
0.050
 Why?
Blood Transfusion, Autologous
2
1993
18
0.050
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2022
23
0.050
 Why?
Carbolines
1
2022
35
0.050
 Why?
Proteasome Endopeptidase Complex
1
2023
155
0.050
 Why?
Adenosine Diphosphate
1
2022
83
0.050
 Why?
Career Choice
1
2024
234
0.040
 Why?
Imidazoles
1
2023
247
0.040
 Why?
Pyrimidinones
1
2022
125
0.040
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2022
108
0.040
 Why?
Actuarial Analysis
2
1993
16
0.040
 Why?
Oncogenes
1
2022
118
0.040
 Why?
Cell Division
2
2001
753
0.040
 Why?
Gene Expression
2
2020
1474
0.040
 Why?
Colony-Forming Units Assay
4
1996
95
0.040
 Why?
Tomography, X-Ray Computed
2
2015
2767
0.040
 Why?
Carcinoembryonic Antigen
1
2001
40
0.040
 Why?
Phthalazines
1
2021
63
0.040
 Why?
Transplantation Immunology
1
2000
29
0.040
 Why?
Clodronic Acid
1
2020
19
0.040
 Why?
Progesterone
1
2002
214
0.040
 Why?
Prospective Studies
5
2022
8035
0.040
 Why?
Fellowships and Scholarships
1
2024
354
0.040
 Why?
Longitudinal Studies
2
2012
2949
0.040
 Why?
Ligands
1
2022
664
0.040
 Why?
Phosphatidylinositol 3-Kinases
1
2022
382
0.040
 Why?
Estradiol
2
2016
512
0.040
 Why?
Extracellular Matrix
1
2024
561
0.040
 Why?
Topoisomerase I Inhibitors
1
1999
19
0.040
 Why?
Thoracotomy
2
1997
83
0.040
 Why?
Polymerase Chain Reaction
1
2003
1039
0.040
 Why?
Leucovorin
2
1997
98
0.040
 Why?
Hematopoietic Stem Cell Mobilization
1
1999
28
0.040
 Why?
Bone Density Conservation Agents
1
2020
81
0.040
 Why?
Mechlorethamine
1
2000
52
0.040
 Why?
Dendritic Cells
2
2000
496
0.040
 Why?
Drug Resistance
1
1999
145
0.040
 Why?
Neoplasms, Experimental
1
2000
167
0.040
 Why?
Myelodysplastic Syndromes
1
2001
148
0.040
 Why?
Receptors, Steroid
1
2019
42
0.040
 Why?
Cluster Analysis
2
2012
500
0.040
 Why?
Heterocyclic Compounds, 3-Ring
1
2019
44
0.040
 Why?
Etanidazole
1
1998
1
0.040
 Why?
Cell Cycle Proteins
1
2022
629
0.040
 Why?
Child
8
2022
22670
0.030
 Why?
Enterocolitis, Pseudomembranous
1
1998
29
0.030
 Why?
Leukemia
1
2001
246
0.030
 Why?
Expectorants
1
1998
23
0.030
 Why?
Loss of Function Mutation
1
2018
45
0.030
 Why?
Aurora Kinase A
1
2018
61
0.030
 Why?
Nervous System
2
1997
69
0.030
 Why?
Disease Susceptibility
1
2020
343
0.030
 Why?
Cross-Over Studies
1
2020
608
0.030
 Why?
Statistics, Nonparametric
1
1999
427
0.030
 Why?
Mediastinum
1
1998
23
0.030
 Why?
Retreatment
1
2018
79
0.030
 Why?
Nausea
1
2018
112
0.030
 Why?
Epithelial Cell Adhesion Molecule
1
2017
10
0.030
 Why?
Myelin Basic Protein
1
2017
44
0.030
 Why?
ADAM17 Protein
1
2017
42
0.030
 Why?
Administration, Intravenous
1
2018
171
0.030
 Why?
Bromodeoxyuridine
1
2017
77
0.030
 Why?
Extremities
2
1989
140
0.030
 Why?
Breast
1
2018
156
0.030
 Why?
SEER Program
1
2018
229
0.030
 Why?
Watchful Waiting
1
2018
90
0.030
 Why?
Cell Hypoxia
1
1998
247
0.030
 Why?
Diarrhea
1
2018
193
0.030
 Why?
Ganglia, Spinal
1
2017
88
0.030
 Why?
Thorax
1
1997
51
0.030
 Why?
Double-Blind Method
1
2022
2057
0.030
 Why?
Coculture Techniques
1
2017
247
0.030
 Why?
Random Allocation
2
1988
365
0.030
 Why?
Phosphoramide Mustards
1
2016
3
0.030
 Why?
Medicare
1
2023
902
0.030
 Why?
Heterografts
1
2017
143
0.030
 Why?
Everolimus
1
2017
112
0.030
 Why?
Immunotoxins
1
1997
55
0.030
 Why?
Cyclohexanes
1
2016
22
0.030
 Why?
Cells, Cultured
2
2017
4142
0.030
 Why?
Cohort Studies
4
2001
5988
0.030
 Why?
Cell Survival
1
2000
1100
0.030
 Why?
Cytochrome P-450 CYP3A
1
2017
93
0.030
 Why?
Placebos
1
2016
193
0.030
 Why?
Fluorescence Resonance Energy Transfer
1
2017
177
0.030
 Why?
Gene Knockdown Techniques
1
2017
333
0.030
 Why?
Ascorbic Acid
1
2017
184
0.030
 Why?
Injections, Intravenous
2
1993
197
0.030
 Why?
Carcinogenesis
1
2018
227
0.030
 Why?
Antineoplastic Agents, Immunological
1
2018
198
0.030
 Why?
Blood Specimen Collection
1
1995
37
0.030
 Why?
Fertility Preservation
1
2016
55
0.030
 Why?
Organoplatinum Compounds
3
1990
65
0.030
 Why?
Antidotes
1
1997
145
0.030
 Why?
Lymphoma, Large B-Cell, Diffuse
1
1998
193
0.030
 Why?
Digestive System
1
1995
29
0.030
 Why?
Transcriptional Activation
1
2017
372
0.030
 Why?
Animals, Newborn
1
2017
891
0.030
 Why?
Genetic Therapy
1
1997
315
0.030
 Why?
Blood Component Transfusion
2
1994
102
0.030
 Why?
Vincristine
1
1995
140
0.030
 Why?
Mortality
1
1997
378
0.030
 Why?
Hormones
1
2015
135
0.030
 Why?
Interleukin-3
1
1994
23
0.030
 Why?
Fertility
1
2016
173
0.030
 Why?
Kidney
2
1995
1494
0.030
 Why?
Diagnosis, Differential
1
2019
1506
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2017
261
0.030
 Why?
Weight Gain
1
2018
561
0.030
 Why?
Leukocyte Count
5
1996
316
0.030
 Why?
Bacterial Infections
1
1996
246
0.030
 Why?
Pulmonary Fibrosis
3
1993
395
0.030
 Why?
Odds Ratio
1
2017
1082
0.030
 Why?
Tosyl Compounds
1
2014
17
0.030
 Why?
Antioxidants
1
2017
550
0.030
 Why?
Child, Preschool
6
2013
11835
0.030
 Why?
Drug Discovery
1
2015
153
0.030
 Why?
Hand-Foot Syndrome
1
2013
2
0.030
 Why?
Adipose Tissue
1
2018
644
0.030
 Why?
Protein Transport
1
2015
441
0.030
 Why?
HEK293 Cells
1
2016
740
0.020
 Why?
Capecitabine
1
2013
56
0.020
 Why?
Transplantation, Heterologous
1
2014
170
0.020
 Why?
Neoplasm Transplantation
1
2014
246
0.020
 Why?
Necrosis
1
2014
243
0.020
 Why?
Cell Nucleus
1
2016
587
0.020
 Why?
Erythropoietin
1
1994
100
0.020
 Why?
Binding Sites
1
2016
1309
0.020
 Why?
Gene Silencing
1
2014
202
0.020
 Why?
Alternative Splicing
1
2015
247
0.020
 Why?
Blood Cells
1
1993
38
0.020
 Why?
Nutritional Status
1
2015
353
0.020
 Why?
CD24 Antigen
1
2012
18
0.020
 Why?
Recombinant Proteins
5
1997
1368
0.020
 Why?
Cross-Sectional Studies
1
2024
5886
0.020
 Why?
Sensitivity and Specificity
2
2000
1995
0.020
 Why?
Anemia
1
1994
190
0.020
 Why?
Radionuclide Imaging
1
1992
115
0.020
 Why?
Diet, Reducing
1
2012
91
0.020
 Why?
Energy Intake
1
2015
507
0.020
 Why?
Models, Biological
1
1999
1763
0.020
 Why?
Antigens, CD34
3
1996
89
0.020
 Why?
Counseling
1
2015
400
0.020
 Why?
Psychotherapy, Group
1
2012
79
0.020
 Why?
Hyaluronan Receptors
1
2012
104
0.020
 Why?
Emergency Medical Services
1
2019
684
0.020
 Why?
Mice, SCID
1
2012
369
0.020
 Why?
Vascular Endothelial Growth Factor Receptor-1
1
2012
74
0.020
 Why?
Surveys and Questionnaires
1
2024
6055
0.020
 Why?
Pandemics
1
2020
1703
0.020
 Why?
Feasibility Studies
4
1998
1109
0.020
 Why?
Tumor Burden
1
2012
324
0.020
 Why?
Fluorescent Antibody Technique
2
1990
365
0.020
 Why?
Logistic Models
1
2016
2133
0.020
 Why?
Biopsy, Needle
1
2011
185
0.020
 Why?
Mice, Inbred NOD
1
2012
613
0.020
 Why?
Chromosomes, Human, Pair 9
1
1990
36
0.020
 Why?
Blast Crisis
1
1990
34
0.020
 Why?
Colorado
1
2020
4538
0.020
 Why?
Immunoblotting
1
2010
295
0.020
 Why?
Chromosomes, Human, Pair 22
1
1990
48
0.020
 Why?
Bilirubin
2
2002
99
0.020
 Why?
Disease Models, Animal
1
2021
4552
0.020
 Why?
Graft Survival
1
1993
517
0.020
 Why?
Pemetrexed
1
2010
40
0.020
 Why?
Cytokines
1
1998
2048
0.020
 Why?
Glutamates
1
2010
66
0.020
 Why?
Antibodies, Anti-Idiotypic
1
1990
50
0.020
 Why?
Magnetics
1
1990
46
0.020
 Why?
Health Status
1
2015
832
0.020
 Why?
Urologic Diseases
1
1990
40
0.020
 Why?
Real-Time Polymerase Chain Reaction
1
2010
337
0.020
 Why?
Multiple Organ Failure
2
2002
120
0.020
 Why?
Guanine
1
2010
85
0.020
 Why?
Kidney Diseases
2
1991
424
0.020
 Why?
Gene Regulatory Networks
1
2012
317
0.020
 Why?
Hypertension
1
2018
1269
0.020
 Why?
Health Behavior
1
2015
787
0.020
 Why?
Microspheres
1
1990
141
0.020
 Why?
RNA, Messenger
1
2017
2803
0.020
 Why?
Chromosome Aberrations
1
1990
165
0.020
 Why?
Spinal Cord Neoplasms
1
1989
41
0.020
 Why?
Blood
1
1990
107
0.020
 Why?
Cell Movement
1
2014
959
0.020
 Why?
Clone Cells
1
1990
263
0.020
 Why?
Promoter Regions, Genetic
1
2014
1244
0.020
 Why?
Pregnancy Trimester, Second
1
2009
83
0.020
 Why?
Central Nervous System Diseases
1
1990
74
0.020
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
1990
127
0.020
 Why?
Hematuria
1
1989
11
0.020
 Why?
Vinblastine
2
2001
75
0.020
 Why?
DNA Methylation
1
2014
667
0.020
 Why?
Rats
1
2017
5582
0.020
 Why?
Creatinine
1
1991
513
0.020
 Why?
False Negative Reactions
1
1988
61
0.020
 Why?
Lymphoma
1
1990
233
0.020
 Why?
Pregnancy Trimester, First
1
2009
138
0.020
 Why?
Immunophenotyping
2
2000
318
0.020
 Why?
Leukopenia
1
1988
33
0.020
 Why?
Niacinamide
1
2009
87
0.020
 Why?
Apoptosis Regulatory Proteins
1
2009
187
0.020
 Why?
Hospitals, Veterans
1
2009
258
0.020
 Why?
False Positive Reactions
1
1988
123
0.020
 Why?
Histones
1
2014
665
0.020
 Why?
Transfection
1
2010
926
0.020
 Why?
Electrophoresis
1
1988
31
0.020
 Why?
Drug Interactions
1
1990
404
0.020
 Why?
Antigens, Differentiation
1
1988
76
0.020
 Why?
Phenylurea Compounds
1
2009
119
0.020
 Why?
Neurons
1
2017
1644
0.020
 Why?
Gene Expression Regulation
1
2017
2588
0.020
 Why?
Estrogen Receptor Modulators
1
2008
14
0.020
 Why?
Perilipin-1
1
2008
16
0.020
 Why?
Macrophages
2
1995
1500
0.020
 Why?
S100 Proteins
1
2008
35
0.020
 Why?
Staining and Labeling
1
1988
153
0.020
 Why?
Antigens, Surface
1
1988
155
0.020
 Why?
Vimentin
1
1988
54
0.020
 Why?
Androstadienes
1
2008
75
0.020
 Why?
Exercise Therapy
1
2012
475
0.020
 Why?
Nervous System Diseases
1
1991
286
0.020
 Why?
Community Health Services
1
2009
231
0.020
 Why?
Central Nervous System
1
1990
281
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2351
0.020
 Why?
Sarcoma, Kaposi
1
1988
83
0.020
 Why?
Bone Marrow Purging
2
1996
3
0.020
 Why?
Lung Diseases
2
1992
780
0.020
 Why?
Clinical Trials, Phase II as Topic
2
2000
75
0.020
 Why?
Biomarkers
1
2018
4282
0.020
 Why?
Heart Diseases
1
1990
341
0.020
 Why?
Academic Medical Centers
1
2009
552
0.020
 Why?
Risk
2
2000
916
0.020
 Why?
Health Knowledge, Attitudes, Practice
1
2015
1415
0.020
 Why?
Stem Cell Transplantation
1
2007
189
0.010
 Why?
Gastrointestinal Diseases
1
2008
221
0.010
 Why?
Phosphoproteins
1
2008
337
0.010
 Why?
Immunoglobulin G
1
1990
887
0.010
 Why?
Bevacizumab
1
2006
168
0.010
 Why?
Quality of Health Care
1
2009
692
0.010
 Why?
Melanoma
2
1988
759
0.010
 Why?
Body Mass Index
1
2012
2437
0.010
 Why?
Carrier Proteins
1
2008
728
0.010
 Why?
Ascites
1
2002
48
0.010
 Why?
Phenotype
1
2010
3138
0.010
 Why?
Brain
1
2014
2934
0.010
 Why?
Carcinoma, Lewis Lung
1
2001
16
0.010
 Why?
Carcinoma, Large Cell
1
2001
17
0.010
 Why?
Transplantation Conditioning
1
2002
191
0.010
 Why?
Phytohemagglutinins
1
2000
29
0.010
 Why?
CD4-CD8 Ratio
1
2000
23
0.010
 Why?
Lymphocyte Culture Test, Mixed
1
2000
49
0.010
 Why?
Hypersensitivity, Delayed
1
2000
29
0.010
 Why?
Drug Synergism
1
2001
354
0.010
 Why?
Skin Tests
1
2000
94
0.010
 Why?
Hemorrhage
2
1998
822
0.010
 Why?
Microcomputers
1
2000
18
0.010
 Why?
Louisiana
1
2000
31
0.010
 Why?
Philadelphia
1
2000
55
0.010
 Why?
Immunoglobulins
1
2000
161
0.010
 Why?
Graft vs Host Disease
1
2002
278
0.010
 Why?
Automation
1
2000
104
0.010
 Why?
Immunity
1
2000
140
0.010
 Why?
Lipopolysaccharide Receptors
1
1999
88
0.010
 Why?
Marriage
1
1980
121
0.010
 Why?
Lung
1
1992
4101
0.010
 Why?
Personnel Selection
1
1980
91
0.010
 Why?
Interleukin-4
1
1999
207
0.010
 Why?
Thalassemia
1
1998
6
0.010
 Why?
Receptors, Purinergic P1
1
1998
30
0.010
 Why?
Heart Failure
1
1992
2324
0.010
 Why?
Microscopy, Fluorescence
1
2000
408
0.010
 Why?
Reference Values
1
2000
798
0.010
 Why?
Multicenter Studies as Topic
1
2000
410
0.010
 Why?
Acute Disease
1
2001
1035
0.010
 Why?
Pilot Projects
2
1994
1889
0.010
 Why?
Infant, Newborn
1
2009
6435
0.010
 Why?
Filgrastim
1
1997
13
0.010
 Why?
Adenoviruses, Human
1
1996
26
0.010
 Why?
Heparin
1
1998
246
0.010
 Why?
Killer Cells, Natural
1
2000
478
0.010
 Why?
Lymphoma, B-Cell
1
1998
137
0.010
 Why?
Tissue Plasminogen Activator
1
1998
248
0.010
 Why?
Freezing
1
1996
83
0.010
 Why?
Lymphocyte Activation
1
2000
1131
0.010
 Why?
Pregnancy
1
2009
7182
0.010
 Why?
Lymphocyte Depletion
1
1996
131
0.010
 Why?
Genes, Reporter
1
1996
277
0.010
 Why?
Carcinoma, Squamous Cell
1
2001
640
0.010
 Why?
Drug Tolerance
1
1995
99
0.010
 Why?
Reticulocyte Count
1
1994
7
0.010
 Why?
Kidney Function Tests
1
1995
156
0.010
 Why?
Topotecan
1
1994
17
0.010
 Why?
Incidence
1
2001
2915
0.010
 Why?
Liver
1
2002
1893
0.010
 Why?
Antigens, CD
1
1996
558
0.010
 Why?
Urinary Bladder Diseases
1
1993
18
0.010
 Why?
Glioblastoma
1
1996
352
0.010
 Why?
Heart
1
1997
626
0.010
 Why?
Boston
1
1993
93
0.010
 Why?
Flow Cytometry
1
1996
1159
0.010
 Why?
Registries
1
2002
2401
0.010
 Why?
Chromatography, High Pressure Liquid
1
1995
591
0.010
 Why?
Iron
1
1994
357
0.010
 Why?
Cell Line
1
1996
2821
0.010
 Why?
Immunologic Factors
1
1993
260
0.000
 Why?
Cystitis
1
1990
24
0.000
 Why?
Palliative Care
1
1998
1017
0.000
 Why?
Prostatic Neoplasms
1
1996
978
0.000
 Why?
Introns
1
1990
253
0.000
 Why?
Metabolic Clearance Rate
1
1989
115
0.000
 Why?
Platinum
1
1989
48
0.000
 Why?
Brain Diseases
1
1990
154
0.000
 Why?
Macrophage-1 Antigen
1
1988
26
0.000
 Why?
Bone Marrow Examination
1
1988
5
0.000
 Why?
Drug Combinations
1
1990
396
0.000
 Why?
Erythrocyte Count
1
1988
21
0.000
 Why?
Platelet Count
1
1988
94
0.000
 Why?
Methods
1
1988
68
0.000
 Why?
Pelvic Neoplasms
1
1988
24
0.000
 Why?
Erythroblasts
1
1988
18
0.000
 Why?
Infant
1
2002
10060
0.000
 Why?
DNA Damage
1
1990
435
0.000
 Why?
Acute Kidney Injury
1
1995
872
0.000
 Why?
In Vitro Techniques
1
1988
1048
0.000
 Why?
Fever
1
1988
318
0.000
 Why?
Pneumonia
1
1992
635
0.000
 Why?
Statistics as Topic
1
1987
283
0.000
 Why?
Elias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (665) concept(s)
_
Co-Authors Expand Description
See all (59) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)